Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment... Purpose: This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation status was investigated. Patients and Methods: Patients received cetuximab (400 mg/m2 initial dose followed by 250 mg/m2/wk thereafter) plus FOLFOX-4 (oxaliplatin 85 mg/m2 on day 1, plus leucovorin 200 mg/m2 and fluorouracil as a 400 mg/m2 bolus followed by a 600 mg/m2 infusion during 22 hours on days 1 and 2; n = 169) or FOLFOX-4 alone (n = 168). Treatment was continued until disease progression or unacceptable toxicity. KRAS mutation status was assessed in the subset of patients with assessable tumor samples (n = 233). Results: The confirmed ORR for cetuximab plus FOLFOX-4 was higher than with FOLFOX-4 alone (46% v 36%). A statistically significant increase in the odds for a response with the addition of cetuximab to FOLFOX-4 could not be established (odds ratio = 1.52; P = .064). In patients with KRAS wild-type tumors, the addition of cetuximab to FOLFOX-4 was associated with a clinically significant increased chance of response (ORR = 61% v 37%; odds ratio = 2.54; P = .011) and a lower risk of disease progression (hazard ratio = 0.57; P = .0163) compared with FOLFOX-4 alone. Cetuximab plus FOLFOX-4 was generally well tolerated. Conclusion: KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addition of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Oncology Wolters Kluwer Health

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/fluorouracil-leucovorin-and-oxaliplatin-with-and-without-cetuximab-in-9casmKbgYg

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
(C) 2009 American Society of Clinical Oncology
ISSN
0732-183X
eISSN
1527-7755
DOI
10.1200/JCO.2008.20.8397
Publisher site
See Article on Publisher Site

Abstract

Purpose: This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation status was investigated. Patients and Methods: Patients received cetuximab (400 mg/m2 initial dose followed by 250 mg/m2/wk thereafter) plus FOLFOX-4 (oxaliplatin 85 mg/m2 on day 1, plus leucovorin 200 mg/m2 and fluorouracil as a 400 mg/m2 bolus followed by a 600 mg/m2 infusion during 22 hours on days 1 and 2; n = 169) or FOLFOX-4 alone (n = 168). Treatment was continued until disease progression or unacceptable toxicity. KRAS mutation status was assessed in the subset of patients with assessable tumor samples (n = 233). Results: The confirmed ORR for cetuximab plus FOLFOX-4 was higher than with FOLFOX-4 alone (46% v 36%). A statistically significant increase in the odds for a response with the addition of cetuximab to FOLFOX-4 could not be established (odds ratio = 1.52; P = .064). In patients with KRAS wild-type tumors, the addition of cetuximab to FOLFOX-4 was associated with a clinically significant increased chance of response (ORR = 61% v 37%; odds ratio = 2.54; P = .011) and a lower risk of disease progression (hazard ratio = 0.57; P = .0163) compared with FOLFOX-4 alone. Cetuximab plus FOLFOX-4 was generally well tolerated. Conclusion: KRAS mutational status was shown to be a highly predictive selection criterion in relation to the treatment decision regarding the addition of cetuximab to FOLFOX-4 for previously untreated patients with metastatic colorectal cancer.

Journal

Journal of Clinical Oncology – Wolters Kluwer Health

Published: Dec 29, 2008

References

  • Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial
    A Adenis; E Aranda Aguilar; YM Robin
  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    D Cunningham; Y Humblet; S Siena
  • Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    G Folprecht; MP Lutz; P Schoffski
  • Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system
    NS Goldstein; M Armin
  • Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    LB Saltz; NJ Meropol; PJ Loehrer Sr
  • Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
    NI Goldstein; M Prewett; K Zuklys
  • Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
    S Li; KR Schmitz; PD Jeffrey
  • High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab
    X Kang; D Patel; S Ng
  • Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
    J Kurai; H Chikumi; K Hashimoto
  • Association of Fc-gamma RIIa and Fc-gamma RIIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan
    F Bibeau; E Crapez; F Di Fiore
  • Cetuximab for the treatment of colorectal cancer
    DJ Jonker; CJ O'Callaghan; CS Karapetis
  • Cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: The EPIC trial
    W Scheithauer; A Sobrero; H Lenz
  • Cetuximab in combination with irinotecan/5-fluorouracil (FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    M Peeters; J-L Raoul; J-L van Laethem
  • CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs FOLFIRI in first-line metastatic colorectal cancer (mCRC)
    E Van Cutsem; G Bodoky; J Kyung Roh
  • Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: A phase Ib/II study of the AIO GI group
    D Arnold; T Hoehler; C Dittrich
  • Phase II trial of cetuximab in combination with fluorouracil, leucovorin and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    J Tabernero; E Van Cutsem; E Diaz-Rubio
  • Targeted therapy of cancer: New roles for pathologists in colorectal cancer
    SR Hamilton
  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    RG Amado; M Wolf; M Peeters
  • KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
    W De Roock; H Piessevaux; J De Schutter
  • Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy
    F Di Fiore; F Blanchard; F Charbonnier
  • KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
    A Lievre; JB Bachet; V Boige
  • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    A Lievre; JB Bachet; D Le Corre
  • KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    E Van Cutsem; I Lang; G D'haens
  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    CS Karapetis; S Khambata-Ford; DJ Jonker
  • Statistical aspects of the analysis of data from retrospective studies of disease
    N Mantel; W Haenszel
  • Chi-square tests with one degree of freedom: Extensions of the Mantel- Haenszel procedure
    N Mantel
  • Nonparametric estimation from incomplete observations
    EL Kaplan; P Meier
  • Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: Comparison with restriction fragment length polymorphism analysis
    CY Chen; SC Shiesh; SJ Wu
  • Locked nucleic acid inhibits amplification of contaminating DNA in real-time PCR
    L Hummelshoj; LP Ryder; HO Madsen
  • Cetuximab (Erbitux) enhances clinical efficacy of oxaliplatin in human colon carcinoma xenografts and reverses oxaliplatin resistance
    M Prewett; R Bassi; F Carrick
  • Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
    CJ Punt; J Tol; CJ Rodenburg
  • Correlation of efficacy to KRAS status (wt vs
    J Tabernero; A Cervantes; F Ciardiello